SPOTLIGHT: CV's Ranexa wins FDA review

CV Therapeutics is making progress in its pursuit of new indications for Ranexa, its angina drug for patients who haven't responded to other therapies. The agency agreed to consider its application to approve Ranexa for cardiac arrhythmia. The agency already has Ranexa under review as a front-line therapy for angina and will consider a label change noting that the therapy reduces the level of glucose in the blood of coronary artery disease patients with diabetes. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.